Biomarin Pharmaceutical
在场
高管
查看带有其 27 名主要高管的组织结构图
Biomarin Pharmaceutical 搜索最多的简介
- Alexander Hardy, President and Chief Executive Officer (starts on ...
- Willard Dere, Director
- Robert Hombach, Director
高管在Biomarin Pharmaceutical变化
- Hank Fuch, President of Worldwide Research & Development, 将于 20249月28 退休 (新闻发布的2024八月22号).
- Greg FribergGreg Friberg 将于20249月29作为 Excecutive Vice President, Chief Research and Development Officer 加入公司 (新闻发布的2024八月22号).
- Brinda Balakrishnan, Executive Vice President and Chief Corporate Strategy & Business Development Officer, 将于 20249月30 退休 (新闻发布的2024八月22号).
创建提醒
跟踪 Biomarin Pharmaceutical 的高管变动
药店
Biomarin Pharmaceutical 拥有 1,835 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 24, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
Biomarin Pharmaceutical 的最新新闻稿
- BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET
- BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
- BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
- BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
- BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
- BioMarin to Host 2024 Investor Day on September 4th in New York
- BioMarin Announces New R&D and Business Development Leadership
- BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress
- BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health
- BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
- View more press releases Close
通过电子邮件
